Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis United States (USA) by Year
Novartis United States (USA): 930 in FY2025, down 7.3% from a year earlier.
Latest, FY2025
930
Period ended Dec 31, 2025
Change on a year earlier
-7.3%
1,003 in FY2024
History
3 years
Since FY2023
Sources
1
Novartis Form 20-F (0001114448-26-000004)
Where the FY2025 figure comes from
“|| USA | 4 845 | 5 302 | 1 479 | 930 | 12 556”
Source: Novartis Form 20-F (0001114448-26-000004) ↗
Reported in Form 20-F.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | United States (USA) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 930 | -7.3% | Novartis Form 20-F (0001114448-26-000004) ↗ |
| FY2024 | Dec 31, 2024 | 1,003 | -9.6% | Novartis Form 20-F (0001114448-26-000004) ↗ |
| FY2023 | Dec 31, 2023 | 1,110 | – | Novartis Form 20-F (0001114448-26-000004) ↗ |
Cite this data
StockData. (2026). Novartis United States (USA), annual FY2023–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/wf-fte-ga-usa
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.